Top

Published in:

01-02-2018

Staging of pancreatic cancer: resectable, borderline resectable, and unresectable disease

Authors: Erik V. Soloff, Atif Zaheer, Jeffrey Meier, Marc Zins, Eric P. Tamm

Published in: Abdominal Radiology | Issue 2/2018

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a relatively common malignancy that carries an overall poor prognosis, with five-year survival below 10%. Despite ongoing research, surgical resection remains the only potentially curative treatment. Therefore, accurate identification of those patients who would benefit from surgical resection is of paramount importance. High-quality imaging and image interpretation is central to this process. Radiology helps in the determination of whether patients are resectable, borderline resectable, or unresectable and guides treatment planning.

https://www.pancan.org/wp-content/uploads/2016/02/2016-GAA-PC-Facts.pdf. Accessed 26 Nov 2017

https://www.cancer.org/cancer/pancreatic-cancer/about/key-statistics.html. Accessed 26 Nov 2017

https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2017/cancer-facts-and-figures-2017.pdf. Accessed 26 Nov 2017

Pietryga JA, Morgan DE (2015) Imaging preoperatively for pancreatic adenocarcinoma. J Gastrointest Oncol 6(4):343–357. https://doi.org/10.3978/j.issn.2078-6891.2015.024 PubMedPubMedCentral

https://www.nccn.org/professionals. Accessed 26 Nov 2017

Macari M, Spieler B, Kim D, et al. (2010) Dual-source dual-energy MDCT of pancreatic adenocarcinoma: initial observations with data generated at 80 kVp and at simulated weighted-average 120 kVp. Am J Roentgenol 194(1):W27–W32. https://doi.org/10.2214/AJR.09.2737 CrossRef

Gupta S, Wagner-Bartak N, Jensen CT, et al. (2016) Dual-energy CT of pancreatic adenocarcinoma: reproducibility of primary tumor measurements and assessment of tumor conspicuity and margin sharpness. Abdom Radiol 41(7):1317–1324. https://doi.org/10.1007/s00261-016-0689-8 CrossRef

Lee ES, Lee JM (2014) Imaging diagnosis of pancreatic cancer: a state of the art review. World J Gastroenterol 20(24):7864–7877. https://doi.org/10.3748/wjg.v20.i24.7864 CrossRefPubMedPubMedCentral

Legrand L, Duchatelle V, Molinié V, et al. (2015) Pancreatic adenocarcinoma: MRI conspicuity and pathologic correlations. Abdom Imaging 40(1):85–94. https://doi.org/10.1007/s00261-014-0196-8 CrossRefPubMed

10.

Chen FM, Ni JM, Zhang ZY, et al. (2016) Presurgical evaluation of pancreatic cancer: a comprehensive imaging comparison of CT versus MRI. AJR Am J Roentgenol 206(3):526–535. https://doi.org/10.2214/AJR.15.15236 CrossRefPubMed

11.

Koelblinger C, Ba-Ssalamah A, Goetzinger P, et al. (2011) Gadobenate dimeglumine-enhanced 3.0-T MR imaging versus multiphasic 64-detector row CT: prospective evaluation in patients suspected of having pancreatic cancer. Radiology 259(3):757–766. https://doi.org/10.1148/radiol.11101189 CrossRefPubMed

12.

Kim JH, Park SH, Yu ES, et al. (2010) Visually isoattenuating pancreatic adenocarcinoma at dynamic-enhanced CT: frequency, clinical and pathologic characteristics, and diagnosis at imaging examinations. Radiology 257(1):87–96. https://doi.org/10.1148/radiol.10100015 CrossRefPubMed

13.

Ward J, Robinson PJ, Guthrie JA, et al. (2005) Liver metastases in candidates for hepatic resection: comparison of helical CT and gadolinium- and SPIO-enhanced MR imaging. Radiology 237(1):170–180CrossRefPubMed

14.

Gonzalo-Marin J, Vila JJ, Perez-Miranda M (2014) Role of endoscopic ultrasound in the diagnosis of pancreatic cancer. World J Gastrointest Oncol 6(9):360–368. https://doi.org/10.4251/wjgo.v6.i9.360 CrossRefPubMedPubMedCentral

15.

DeWitt J, Devereaux B, Chriswell M, et al. (2004) Comparison of endoscopic ultrasonography and multidetector computed tomography for detecting and staging pancreatic cancer. Ann Intern Med 141:753–763CrossRefPubMed

16.

Arabul M, Karakus F, Alper E, et al. (2012) Comparison of multidetector CT and endoscopic ultrasonography in malignant pancreatic mass lesions. Hepatogastroenterology 59:1599–1603PubMed

17.

Adler DG, Jacobson BC, Davila RE, et al. (2005) ASGE guideline: complications of EUS. Gastrointest Endosc 6:8–12. https://doi.org/10.1016/S0016-5107(04)02393-4

18.

Katanuma A, Maguchi H, Hashigo S, Kaneko M, Kin T, Yane K, Kato R, Kato S, Harada R, Osanai M, et al. (2102) Tumor seeding after endoscopic ultrasound-guided fine-needle aspiration of cancer in the body of the pancreas. Endoscopy 44 Suppl 2 UCTN:E160–1. https://doi.org/10.1055/s-0031-1291716

19.

Okano K, Kakinoki K, Akamoto S, et al. (2011) 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of small pancreatic cancer. World J Gastroenterol 17(2):231–235. https://doi.org/10.3748/wjg.v17.i2.231 CrossRefPubMedPubMedCentral

20.

Jha P, Bijan B (2015) PET/CT for pancreatic malignancy: potential and pitfalls. J Nucl Med Technol 43:92–97. https://doi.org/10.2967/jnmt.114.145458 CrossRefPubMed

21.

Tamm EP, Balachandran A, Bhosale PR, et al. (2012) Imaging of pancreatic adenocarcinoma: update on staging/resectability. Radiol Clin North Am. 50(3):407–428. https://doi.org/10.1016/j.rcl.2012.03.008 CrossRefPubMed

22.

Farma JM, Santillan AA, Melis M, et al. (2008) PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms. Ann Surg Oncol 15(9):2465–2471. https://doi.org/10.1245/s10434-008-9992-0 CrossRefPubMed

23.

Kauhanen SP, Komar G, Seppänen MP, et al. (2009) A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Ann Surg 250:957–963. https://doi.org/10.1097/SLA.0b013e3181b2fafa CrossRefPubMed

24.

Sahani DV, Bonaffini PA, Catalano OA, Guimaraes AR, Blake MA (2012) State-of-the-art PET/CT of the pancreas: current role and emerging indications. Radiographics 32(4):1133–58; discussion 1158–60. https://doi.org/10.1148/rg.324115143

25.

Nakamoto Y, Higashi T, Sakahara H, et al. (1999) Contribution of PET in the detection of liver metastases from pancreatic tumours. Clin Radiol 54(4):248–252CrossRefPubMed

26.

Yoneyama T, Tateishi U, Endo I, Inoue T (2014) Staging accuracy of pancreatic cancer: comparison between non-contrast-enhanced and contrast-enhanced PET/CT. Eur J Radiol 83(10):1734–1739. https://doi.org/10.1016/j.ejrad.2014.04.026 CrossRefPubMed

27.

AJCC Cancer Staging Manual, Eighth Edition (2016) Springer, Switzerland ISBN 978-3-319-40617-6

28.

Varadhachary GR, Tamm EP, Abbruzzese JL, et al. (2006) Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 13(8):1035–1046. https://doi.org/10.1245/ASO.2006.08.011 CrossRefPubMed

29.

https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf

30.

Cesmebasi A, Malefant J, Patel SD, et al. (2015) The surgical anatomy of the lymphatic system of the pancreas. Clin Anat 28(4):527–537. https://doi.org/10.1002/ca.22461 CrossRefPubMed

31.

Al-Hawary MM, Francis IR, Chari ST, et al. (2014) Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association. Radiology 270(1):248–260. https://doi.org/10.1148/radiol.13131184 CrossRefPubMed

32.

Hazirolan T, Metin Y, Karaosmanoglu AD, et al. (2009) Mesenteric arterial variations detected at MDCT angiography of abdominal aorta. Am J Roentgenol 192(4):1097–1102. https://doi.org/10.2214/AJR.08.1532 CrossRef

33.

Sugae T, Fujii T, Kodera Y, et al. (2012) Classification of the celiac axis stenosis owing to median arcuate ligament compression, based on severity of the stenosis with subsequent proposals for management during pancreatoduodenectomy. Surgery 151(4):543–549. https://doi.org/10.1016/j.surg.2011.08.012 CrossRefPubMed

34.

Okafuji T, Sakai S, Yoshimitsu K, et al. (2004) Pulmonary metastasis from pancreatic cancer: a case showing biphasic radiological and histological patterns. CMIG Extra Cases 28:68–71CrossRef

35.

Javed AA, Bagante F, Hruban RH, et al. (2015) Postoperative omental infarct after distal pancreatectomy: appearance, etiology management, and review of literature. J Gastrointest Surg 19(11):2028–2037. https://doi.org/10.1007/s11605-015-2920-2 CrossRefPubMed

36.

Brook OR, Brook A, Vollmer CM, et al. (2015) Structured reporting of multiphasic CT for pancreatic cancer: potential effect on staging and surgical planning. Radiology 274(2):464–472. https://doi.org/10.1148/radiol.14140206 CrossRefPubMed

37.

Ishikawa O, Ohigashi H, Imaoka S, et al. (1992) Preoperative indications for extended pancreatectomy for locally advanced pancreas cancer involving the portal vein. Ann Surg 215(3):231–236CrossRefPubMedPubMedCentral

38.

Katz MH, Fleming JB, Bhosale P, et al. (2012) Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer 118(23):5749–5756. https://doi.org/10.1002/cncr.27636 CrossRefPubMed

39.

Chang ST, Jeffrey RB, Patel BN, et al. (2016) Preoperative multidetector CT diagnosis of extrapancreatic perineural or duodenal invasion is associated with reduced postoperative survival after pancreaticoduodenectomy for pancreatic adenocarcinoma: preliminary experience and implications for patient care. Radiology 281(3):816–825. https://doi.org/10.1148/radiol.2016152790 CrossRefPubMed

Title: Staging of pancreatic cancer: resectable, borderline resectable, and unresectable disease
Authors: Erik V. Soloff
Atif Zaheer
Jeffrey Meier
Marc Zins
Eric P. Tamm
Publication date: 01-02-2018
Publisher: Springer US
Published in: Abdominal Radiology / Issue 2/2018
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI: https://doi.org/10.1007/s00261-017-1410-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2018

Gastroenterology and pancreatic adenocarcinoma: what the radiologist needs to know

Introduction to the special section on pancreatic cancer

Split-bolus pancreas CTA protocol for local staging of pancreatic cancer and detection and characterization of liver lesions

The role of imaging in the clinical practice of radiation oncology for pancreatic cancer

Surgery for pancreatic cancer: critical radiologic findings for clinical decision making

Imaging findings of recurrent pancreatic cancer following resection

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials